Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarction.
D002986:Clinical Trials as Topic; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007263:Infusions, Parenteral; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator